Logo

PRPO

Precipio, Inc.

PRPO

Precipio, Inc. • NASDAQ
$24.38 ▼ -0.47% (-0.12)
Market Cap $37.46 M
52w High $28.50
52w Low $3.90
Dividend Yield 0%
P/E -30.09
Volume 2.08K
Outstanding Shares 1.54M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $6.164M ▲ $3.066M ▼ $-79K ▼ -1.282% ▼ $-0.05 ▼ $240K ▼
Q2-2025 $5.654M ▲ $3.253M ▲ $74K ▲ 1.309% ▲ $0.049 ▲ $519K ▲
Q1-2025 $4.257M ▼ $2.999M ▲ $-884K ▼ -20.766% ▼ $-0.59 ▼ $-442K ▼
Q4-2024 $5.45M ▲ $2.982M ▲ $-365K ▲ -6.697% ▲ $-0.25 ▲ $46K ▲
Q3-2024 $5.209M $2.874M $-626K -12.018% $-0.42 $-216K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $2.305M ▲ $21.153M ▲ $7.404M ▲ $13.749M ▲
Q2-2025 $1.13M ▲ $18.816M ▲ $6.528M ▲ $12.288M ▲
Q1-2025 $1.017M ▼ $17.785M ▲ $6.087M ▲ $11.698M ▼
Q4-2024 $1.389M ▲ $16.996M ▲ $4.902M ▼ $12.094M ▲
Q3-2024 $1.053M $16.951M $5.006M $11.945M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-79K ▼ $10K ▼ $-54K ▲ $1.219M ▲ $1.175M ▲ $-44K ▼
Q2-2025 $74K ▲ $353K ▲ $-59K ▲ $-181K ▲ $113K ▲ $294K ▲
Q1-2025 $-884K ▼ $-44K ▼ $-138K ▼ $-190K ▼ $-372K ▼ $-182K ▼
Q4-2024 $-365K ▲ $565K ▲ $-44K ▲ $-185K ▼ $336K ▲ $521K ▲
Q3-2024 $-626K $41K $-109K $-158K $-226K $-68K

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Diagnostic Testing
Diagnostic Testing
 $0 ▲$0 ▲$10.00M ▲$10.00M ▲
Service revenue net
Service revenue net
 $10.00M ▲$10.00M ▲$10.00M ▲$10.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Precipio’s income statement looks like that of a very small, still-developing diagnostics company. Revenue remains modest and has not yet scaled meaningfully, though it has inched up over time. The company is able to generate some gross profit, but not nearly enough to cover its operating expenses, so it continues to report losses. Those losses appear to be slowly narrowing, suggesting better cost control or improved mix, but earnings per share remain deeply negative, reflecting both ongoing losses and a history of share restructurings. Overall, the business is still in the “building toward scale” phase rather than in a mature, consistently profitable phase.

Balance Sheet

Balance Sheet The balance sheet is lean and reflects a very small enterprise. Total assets and shareholders’ equity are limited, and cash balances have been thin, leaving only a modest financial cushion. On the positive side, reported debt is minimal to nonexistent, which reduces the risk of heavy interest burdens or near‑term repayment pressures. However, the combination of a small asset base and light cash reserves means the company’s financial flexibility is constrained and it is more sensitive to operational setbacks or delays in revenue growth.

Cash Flow

Cash Flow Cash flow has historically been weak, consistent with an early-stage, loss-making company. Operating cash flow has hovered around breakeven to modestly negative, indicating the core business has not yet become a strong cash generator. Capital spending appears very light, so free cash flow largely mirrors operating cash flow. This keeps investment needs manageable but also signals limited internal resources for aggressive expansion. Overall, the company has relied on external funding in the past, and its ability to sustain itself will depend heavily on turning its improving operating performance into consistently positive cash generation.

Competitive Edge

Competitive Edge Competitively, Precipio occupies a focused niche in cancer diagnostics, particularly in blood cancers and highly sensitive mutation testing. Its main strengths come from proprietary technologies like HemeScreen, IV-Cell, and ICE COLD-PCR, which aim to deliver faster, more accurate, and more cost-effective results compared with traditional methods. Patents, exclusive licenses, and clinical collaborations support a meaningful, though still emerging, moat. The main challenge is scale: the company operates in a market dominated by much larger diagnostics firms, so winning broad laboratory adoption, navigating reimbursement, and building brand recognition are ongoing hurdles. Its differentiated technology provides a clear angle, but market penetration remains the key test.

Innovation and R&D

Innovation and R&D Innovation is a clear bright spot. Precipio’s R&D strategy is tightly integrated with its clinical lab operations, using real-world cases to design and refine products. Its three core platforms are being expanded with new test panels and broader applications, especially around liquid biopsies and additional blood cancer indications. The company is also pushing into international markets through distribution deals, which can leverage partners’ sales networks rather than building everything in-house. R&D appears focused and practical rather than speculative, but success hinges on continued clinical validation, regulatory acceptance, and customer uptake, all of which can be unpredictable and take time.

Summary

Overall, Precipio combines promising, specialized cancer-diagnostics technology with a financially fragile, small-company profile. The technology and intellectual property form a solid innovation story, and there are signs of operational improvement as losses and cash burn appear to be narrowing. At the same time, the revenue base is still small, profits have not yet materialized, and the balance sheet offers only a modest buffer. Future outcomes will largely depend on whether the company can convert its scientific advantages into broader commercial adoption, stable positive cash flow, and a stronger financial foundation in a competitive, heavily regulated healthcare market.

NEWS

November 14, 2025 · 4:30 PM UTC

Precipio Announces its Q3-2025 Financial Results

Read more

November 4, 2025 · 5:00 PM UTC

Precipio Announces Q3-2025 Shareholder Update Call

Read more